Developer docs
API playgroundTry for free, no card

Search company profiles

NONO

Full company profile

uuid0008pky

Namestring
NONO
Legal namestring
NoNO Inc.
Websiteurl
nonoinc.ca
Company typeenum
Private
Founded yearint
2003
Descriptiontext

NoNO Inc. is a privately-held, clinical-stage biotechnology company founded in 2003 and headquartered in Toronto, Ontario, Canada. The company is developing a portfolio of first-in-class peptide therapeutics based on a proprietary Postsynaptic Density Protein 95 (PSD-95) inhibitor platform, with the lead asset nerinetide (NA-1) currently in global Phase 3 trials for acute ischemic stroke patients not receiving thrombolytic drugs. The technology targets protein-protein interactions between NMDA glutamate receptors and neuronal nitric oxide synthase (nNOS), aiming to prevent excitotoxic neuronal damage during the acute injury phase while promoting neural plasticity in the recovery phase, with a therapeutic window extending up to 12 hours post-stroke. Beyond the lead IV compound, the pipeline includes NoNO-42 (a next-generation protease-resistant PSD-95 inhibitor in Phase 1, designed to be delivered via the StrokePen autoinjector and compatible with alteplase) and NoNO-SC (a subcutaneous formulation targeting subacute and chronic neurological indications including stroke recovery, vascular dementia, Alzheimer's disease, and retinal ischemia).

The company operates with a lean team of 11-50 employees and runs global clinical trials across 48 sites in North America, Europe, Asia, and Australia. Scientific leadership is anchored by founder, President, and CEO Dr. Michael Tymianski (Canada Research Chair Tier 1 in Translational Stroke Research, Order of Canada), supported by co-founder Dr. Michael W. Salter and a bench of regulatory and clinical operations executives recruited from Sanofi Pasteur, UCSF, and Medicago. The intellectual property portfolio comprises more than 300 granted patents globally protecting the PSD-95 inhibitor platform, and the underlying science has been validated through peer-reviewed publications in The Lancet and Science Translational Medicine, with ESCAPE-NA1 Phase 3 results demonstrating a 19.6% improvement in functional independence, 22% reduction in infarct volume, and 40% mortality reduction in stroke patients not previously treated with alteplase.

The business model is biopharmaceutical product sales upon regulatory approval: upon commercialization, nerinetide will be administered intravenously in hospital settings to acute ischemic stroke patients selected for endovascular thrombectomy, with future expansion through the StrokePen autoinjector and subcutaneous NoNO-SC formulations enabling pre-hospital and non-medical-setting administration. No commercial pricing has been disclosed because no product is currently approved. The company is funded primarily through equity capital (most recently a $9.78 million round in May 2013), government grants, and undisclosed financings, with strategic academic partnerships with the University of Toronto, University of Calgary, the Hospital for Sick Children Research Institute, and the University of British Columbia providing preclinical and clinical research infrastructure.

Short descriptiontext

NoNO Inc. is a Toronto-based clinical-stage biotechnology company developing first-in-class PSD-95 inhibitor peptide therapeutics, led by nerinetide in Phase 3 trials, for treating acute ischemic stroke and other neurological disorders in hospital and pre-hospital settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stroke therapeutics, neuroprotective drugs, PSD-95 inhibitors, clinical-stage biopharmaceuticals, acute ischemic stroke treatment
Industry3 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAG
Stroke & Vascular Neurology
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals (Stroke Therapeutics)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Upon regulatory approval, NoNO will generate revenue through the sale of proprietary neuroprotective drugs (nerinetide, NoNO-42, NoNO-SC) to hospitals, healthcare systems, and pharmacies for treatment of acute ischemic stroke and other neurological conditions. Revenue will be generated from product sales as a biopharmaceutical company commercializing novel therapeutics.

nonoinc.ca
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NoNO Inc. is a clinical-stage biotechnology company developing a portfolio of first-in-class PSD-95 inhibitor therapeutics for the treatment of acute ischemic stroke and other central nervous system disorders. The lead compound nerinetide is in global Phase 3 trials for intravenous administration to stroke patients not previously treated with clot-dissolving drugs, while next-generation compounds (NoNO-42/StrokePen and NoNO-SC) extend applicability to all stroke patients and chronic neurological conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 19.6% improvement in functional independence at 90 days (59.4% vs 49.8% placebo) in patients not receiving alteplase
+3 more records
Product overview1 text field

NoNO Inc. is a clinical-stage Ontario biotechnology company developing a portfolio of PSD-95 inhibitor therapeutics for stroke and other CNS disorders. The product pipeline consists of three core compounds: Nerinetide (Phase 3, IV administration for acute ischemic stroke in patients not receiving thrombolytics), NoNO-42/StroKePen (Phase 1, designed for use with or without thrombolytics), and NoNO-SC (preclinical/subcutaneous formulation for chronic neurological conditions). The platform centers on PSD-95 inhibition to protect neurons from excitotoxic damage and promote neural plasticity for functional recovery.

Product and service3 records
1Nerinetide
CategoryAcute Ischemic Stroke Neuroprotective Drug
Description

A first-in-class 20 amino acid peptide inhibitor of PSD-95 (postsynaptic density protein 95) for intravenous infusion to improve outcomes in acute ischemic stroke. Currently completing global Phase 3 ESCAPE-NEXT trial for patients not previously treated with clot-dissolving drugs (thrombolytics). Demonstrated 19.6% improvement in functional independence, 22% reduction in infarct volume, and 40% mortality reduction in ESCAPE-NA1 trial patients not receiving alteplase.

2NoNO-42 (StrokePen)
CategoryAcute Ischemic Stroke Neuroprotective Drug (Next-Generation)
Description

Next-generation protease-resistant PSD-95 inhibitor in Phase 1 clinical trials, designed to be administered with or without thrombolytic agents. Intended for use in all acute ischemic stroke patients. Being developed for delivery via autoinjector (StrokePen) for administration by any caregiver at home, en route to hospital, or upon arrival in emergency department.

3NoNO-SC
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Michael Tymianski serves as Professor of Surgery and Physiology at University of Toronto. The company maintains unique access to academic preclinical and clinical research teams through this relationship. The institution supports Canada's Research Chair (Tier 1) in Translational Stroke Research held by Dr. Tymianski.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Michael Hill serves as Global Principal Investigator for ESCAPE-NEXT and ESCAPE-NA1 trials, Professor of Neurology at Cumming School of Medicine. The university coordinates global clinical trial operations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Michael W. Salter (co-founder) serves as Chief of Research at The Hospital for Sick Children Research Institute and holds the Northbridge Chair in Pediatric Research.

4University of British Columbia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Yu-Tian Wang serves as professor in the Department of Medicine and Brain Research Centre at UBC, which holds the Heart and Stroke Foundation Chair in Stroke Research.

nonoinc.ca
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Biogen is a large CNS-focused biopharma with extensive neurology commercial infrastructure and a pipeline including Alzheimer's therapies (e.g., lecanemab). Comparable as a broad incumbent in neurology/CNS that could pursue partnership, licensing, or competitive threats in NoNO's expanding indication footprint.

TypeBroad incumbent
Description

Medtronic's Neurovascular division manufactures stent retrievers and other endovascular thrombectomy devices used in the patients NoNO targets with nerinetide. Comparable as a dominant incumbent in the mechanical thrombectomy arm of acute stroke care.

TypeDirect peer
Description

ReNeuron develops CTX stem cell therapy for stroke disability and other CNS conditions. Similar to NoNO, it is a clinical-stage biotech focused on neurorestoration in chronic stroke recovery, addressing overlapping patient populations and pursuing similar regulatory pathways.

TypeEmerging player
Description

SanBio is developing regenerative cell therapies (SB623) for chronic stroke disability and traumatic brain injury. Comparable as a clinical-stage emerging player addressing post-stroke functional recovery, overlapping with NoNO-SC's chronic-condition positioning.

TypeBroad incumbent
Description

Penumbra develops and markets aspiration-based thrombectomy systems for acute ischemic stroke, directly competing in the endovascular thrombectomy procedure population NoNO's nerinetide is administered alongside. Comparable as a US-listed specialty device incumbent in the same procedural setting.

TypeBroad incumbent
Description

Stryker's Neurovascular division (acquired with Cerenovus) makes stent retrievers and other devices for mechanical thrombectomy in acute ischemic stroke. Comparable as a large incumbent serving the same procedural patient population as NoNO's lead compound.

TypeDirect peer
Description

ZZ Biotech is developing 3K3A-APC, a recombinant protein neuroprotective for ischemic stroke. Like NoNO, it targets excitotoxic/inflammatory neuronal damage pathways and has completed Phase 2 trials, making it a direct head-to-head peer in the acute neuroprotective space.

TypeBroad incumbent
Description

Genentech/Roche markets Activase (alteplase), the leading thrombolytic for acute ischemic stroke and the standard of care that NoNO's neuroprotective aims to complement. Comparable as the incumbent in the broader acute ischemic stroke treatment paradigm NoNO is targeting.

9Boehringer Ingelheim
TypeBroad incumbent
Description

Boehringer Ingelheim markets Actilyse (alteplase) outside the US and has deep CNS/cardiovascular commercial infrastructure. Comparable as a global incumbent whose standard-of-care thrombolytic franchise defines the market NoNO is seeking to expand with adjunctive neuroprotection.

10Athersys
TypeDirect peer
Description

Athersys developed MultiStem cell therapy for ischemic stroke, a clinical-stage regenerative medicine approach directly competing with NoNO's PSD-95 platform. Both target neuroprotection/recovery in acute stroke populations and have run global Phase 2/3 trials with similar regulatory and commercial challenges.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NONO

Clinical-stage Biopharmaceuticals (Stroke Therapeutics)nonoinc.ca

NoNO Inc. is a Toronto-based clinical-stage biotechnology company developing first-in-class PSD-95 inhibitor peptide therapeutics, led by nerinetide in Phase 3 trials, for treating acute ischemic stroke and other neurological disorders in hospital and pre-hospital settings.

What NONO does

NoNO Inc. is a privately-held, clinical-stage biotechnology company founded in 2003 and headquartered in Toronto, Ontario, Canada. The company is developing a portfolio of first-in-class peptide therapeutics based on a proprietary Postsynaptic Density Protein 95 (PSD-95) inhibitor platform, with the lead asset nerinetide (NA-1) currently in global Phase 3 trials for acute ischemic stroke patients not receiving thrombolytic drugs. The technology targets protein-protein interactions between NMDA glutamate receptors and neuronal nitric oxide synthase (nNOS), aiming to prevent excitotoxic neuronal damage during the acute injury phase while promoting neural plasticity in the recovery phase, with a therapeutic window extending up to 12 hours post-stroke. Beyond the lead IV compound, the pipeline includes NoNO-42 (a next-generation protease-resistant PSD-95 inhibitor in Phase 1, designed to be delivered via the StrokePen autoinjector and compatible with alteplase) and NoNO-SC (a subcutaneous formulation targeting subacute and chronic neurological indications including stroke recovery, vascular dementia, Alzheimer's disease, and retinal ischemia).

The company operates with a lean team of 11-50 employees and runs global clinical trials across 48 sites in North America, Europe, Asia, and Australia. Scientific leadership is anchored by founder, President, and CEO Dr. Michael Tymianski (Canada Research Chair Tier 1 in Translational Stroke Research, Order of Canada), supported by co-founder Dr. Michael W. Salter and a bench of regulatory and clinical operations executives recruited from Sanofi Pasteur, UCSF, and Medicago. The intellectual property portfolio comprises more than 300 granted patents globally protecting the PSD-95 inhibitor platform, and the underlying science has been validated through peer-reviewed publications in The Lancet and Science Translational Medicine, with ESCAPE-NA1 Phase 3 results demonstrating a 19.6% improvement in functional independence, 22% reduction in infarct volume, and 40% mortality reduction in stroke patients not previously treated with alteplase.

The business model is biopharmaceutical product sales upon regulatory approval: upon commercialization, nerinetide will be administered intravenously in hospital settings to acute ischemic stroke patients selected for endovascular thrombectomy, with future expansion through the StrokePen autoinjector and subcutaneous NoNO-SC formulations enabling pre-hospital and non-medical-setting administration. No commercial pricing has been disclosed because no product is currently approved. The company is funded primarily through equity capital (most recently a $9.78 million round in May 2013), government grants, and undisclosed financings, with strategic academic partnerships with the University of Toronto, University of Calgary, the Hospital for Sick Children Research Institute, and the University of British Columbia providing preclinical and clinical research infrastructure.

NONO firmographics

Firmographics
Name
NONO
Legal name
NoNO Inc.
Website
https://nonoinc.ca
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
NoNO Inc. is a Toronto-based clinical-stage biotechnology company developing first-in-class PSD-95 inhibitor peptide therapeutics, led by nerinetide in Phase 3 trials, for treating acute ischemic stroke and other neurological disorders in hospital and pre-hospital settings.
Ownership category
akta.pro rank

NONO industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals (Stroke Therapeutics)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAG
Stroke & Vascular Neurology

Keywords

  • Stroke therapeutics
  • Neuroprotective drugs
  • PSD-95 inhibitors
  • Clinical-stage biopharmaceuticals
  • Acute ischemic stroke treatment

Where NONO is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

NONO business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Upon regulatory approval, NoNO will generate revenue through the sale of proprietary neuroprotective drugs (nerinetide, NoNO-42, NoNO-SC) to hospitals, healthcare systems, and pharmacies for treatment of acute ischemic stroke and other neurological conditions. Revenue will be generated from product sales as a biopharmaceutical company commercializing novel therapeutics.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

NONO product offering

Product offering

Core offering

NoNO Inc. is a clinical-stage biotechnology company developing a portfolio of first-in-class PSD-95 inhibitor therapeutics for the treatment of acute ischemic stroke and other central nervous system disorders. The lead compound nerinetide is in global Phase 3 trials for intravenous administration to stroke patients not previously treated with clot-dissolving drugs, while next-generation compounds (NoNO-42/StrokePen and NoNO-SC) extend applicability to all stroke patients and chronic neurological conditions.

Product overview

NoNO Inc. is a clinical-stage Ontario biotechnology company developing a portfolio of PSD-95 inhibitor therapeutics for stroke and other CNS disorders. The product pipeline consists of three core compounds: Nerinetide (Phase 3, IV administration for acute ischemic stroke in patients not receiving thrombolytics), NoNO-42/StroKePen (Phase 1, designed for use with or without thrombolytics), and NoNO-SC (preclinical/subcutaneous formulation for chronic neurological conditions). The platform centers on PSD-95 inhibition to protect neurons from excitotoxic damage and promote neural plasticity for functional recovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nerinetide A first-in-class 20 amino acid peptide inhibitor of PSD-95 (postsynaptic density protein 95) for intravenous infusion to improve outcomes in acute ischemic stroke. Currently completing global Phase 3 ESCAPE-NEXT trial for patients not previously treated with clot-dissolving drugs (thrombolytics). Demonstrated 19.6% improvement in functional independence, 22% reduction in infarct volume, and 40% mortality reduction in ESCAPE-NA1 trial patients not receiving alteplase.
  • NoNO-42 (StrokePen) Next-generation protease-resistant PSD-95 inhibitor in Phase 1 clinical trials, designed to be administered with or without thrombolytic agents. Intended for use in all acute ischemic stroke patients. Being developed for delivery via autoinjector (StrokePen) for administration by any caregiver at home, en route to hospital, or upon arrival in emergency department.
  • NoNO-SC

Quantifiable outcome

  • 19.6% improvement in functional independence at 90 days (59.4% vs 49.8% placebo) in patients not receiving alteplase
  • +3 more outcomes

Companies that use NONO

Customer profile

Segments2 records

Ideal customer profiles2 records

NONO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NONO partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • University of TorontocoreStrategic or Co-development PartnerDr. Michael Tymianski serves as Professor of Surgery and Physiology at University of Toronto. The company maintains unique access to academic preclinical and clinical research teams through this relationship. The institution supports Canada's Research Chair (Tier 1) in Translational Stroke Research held by Dr. Tymianski.
  • University of CalgarycoreStrategic or Co-development PartnerDr. Michael Hill serves as Global Principal Investigator for ESCAPE-NEXT and ESCAPE-NA1 trials, Professor of Neurology at Cumming School of Medicine. The university coordinates global clinical trial operations.
  • Hospital for Sick Children Research InstitutecoreStrategic or Co-development PartnerDr. Michael W. Salter (co-founder) serves as Chief of Research at The Hospital for Sick Children Research Institute and holds the Northbridge Chair in Pediatric Research.
  • University of British ColumbiacoreStrategic or Co-development PartnerDr. Yu-Tian Wang serves as professor in the Department of Medicine and Brain Research Centre at UBC, which holds the Heart and Stroke Foundation Chair in Stroke Research.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

NONO competitors and assessment

Company assessment

Broad incumbents

  • Biogen: Biogen is a large CNS-focused biopharma with extensive neurology commercial infrastructure and a pipeline including Alzheimer's therapies (e.g., lecanemab). Comparable as a broad incumbent in neurology/CNS that could pursue partnership, licensing, or competitive threats in NoNO's expanding indication footprint.
  • Medtronic: Medtronic's Neurovascular division manufactures stent retrievers and other endovascular thrombectomy devices used in the patients NoNO targets with nerinetide. Comparable as a dominant incumbent in the mechanical thrombectomy arm of acute stroke care.
  • Penumbra: Penumbra develops and markets aspiration-based thrombectomy systems for acute ischemic stroke, directly competing in the endovascular thrombectomy procedure population NoNO's nerinetide is administered alongside. Comparable as a US-listed specialty device incumbent in the same procedural setting.
  • Stryker (Neurovascular): Stryker's Neurovascular division (acquired with Cerenovus) makes stent retrievers and other devices for mechanical thrombectomy in acute ischemic stroke. Comparable as a large incumbent serving the same procedural patient population as NoNO's lead compound.
  • Genentech (Roche): Genentech/Roche markets Activase (alteplase), the leading thrombolytic for acute ischemic stroke and the standard of care that NoNO's neuroprotective aims to complement. Comparable as the incumbent in the broader acute ischemic stroke treatment paradigm NoNO is targeting.
  • Boehringer Ingelheim: Boehringer Ingelheim markets Actilyse (alteplase) outside the US and has deep CNS/cardiovascular commercial infrastructure. Comparable as a global incumbent whose standard-of-care thrombolytic franchise defines the market NoNO is seeking to expand with adjunctive neuroprotection.

Direct peers

  • ReNeuron: ReNeuron develops CTX stem cell therapy for stroke disability and other CNS conditions. Similar to NoNO, it is a clinical-stage biotech focused on neurorestoration in chronic stroke recovery, addressing overlapping patient populations and pursuing similar regulatory pathways.
  • ZZ Biotech: ZZ Biotech is developing 3K3A-APC, a recombinant protein neuroprotective for ischemic stroke. Like NoNO, it targets excitotoxic/inflammatory neuronal damage pathways and has completed Phase 2 trials, making it a direct head-to-head peer in the acute neuroprotective space.
  • Athersys: Athersys developed MultiStem cell therapy for ischemic stroke, a clinical-stage regenerative medicine approach directly competing with NoNO's PSD-95 platform. Both target neuroprotection/recovery in acute stroke populations and have run global Phase 2/3 trials with similar regulatory and commercial challenges.

Emerging players

  • SanBio: SanBio is developing regenerative cell therapies (SB623) for chronic stroke disability and traumatic brain injury. Comparable as a clinical-stage emerging player addressing post-stroke functional recovery, overlapping with NoNO-SC's chronic-condition positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NONO social profiles

Digital presence

NONO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NONO leadership team

Management profile

Number of profiles

Profiles5 records

NONO funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NONO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NONO

What does NONO do?

NoNO Inc. is a clinical-stage biotechnology company developing a portfolio of first-in-class PSD-95 inhibitor therapeutics for the treatment of acute ischemic stroke and other central nervous system disorders. The lead compound nerinetide is in global Phase 3 trials for intravenous administration to stroke patients not previously treated with clot-dissolving drugs, while next-generation compounds (NoNO-42/StrokePen and NoNO-SC) extend applicability to all stroke patients and chronic neurological conditions.

Is NONO a public or private company?

NONO is a private company. It is classified as venture growth investor backed and is currently operating.

When was NONO founded?

NONO was founded in 2003. It employs 51 to 100 people.

Where is NONO based?

NONO is headquartered in Toronto, Canada, in the North America region.

How does NONO make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are NONO's main competitors?

Broad incumbents on record are Biogen, Medtronic, Penumbra, Stryker (Neurovascular), Genentech (Roche) and Boehringer Ingelheim. Direct peers are ReNeuron, ZZ Biotech and Athersys. SanBio is listed as an emerging player.

Does NONO have an API?

No public API is recorded for NONO.

What industry is NONO in?

NONO's product category is Clinical-stage Biopharmaceuticals (Stroke Therapeutics). Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals